Log In Get Started
Stock Markets March 30, 2026

United Therapeutics Rallies After TETON-1 Shows Tyvaso Meets Primary Endpoint in IPF Trial

Shares jump 12% as pivotal data demonstrate meaningful lung-function gains and reduced clinical worsening; company to seek priority FDA review

By Avery Klein UTHR
United Therapeutics Rallies After TETON-1 Shows Tyvaso Meets Primary Endpoint in IPF Trial
UTHR

United Therapeutics shares climbed 12% Monday after the company reported that its pivotal TETON-1 study of nebulized Tyvaso achieved the trial's primary endpoint in patients with idiopathic pulmonary fibrosis (IPF). The therapy produced a statistically significant improvement in absolute forced vital capacity (FVC) versus placebo and reduced the risk of clinical worsening. Integrated analyses with the earlier TETON-2 trial reinforced the treatment effect through week 52. United Therapeutics intends to file a supplemental New Drug Application for priority review with the U.S. Food and Drug Administration by the end of this summer to add IPF to Tyvaso's labeled indications.

Key Points

  • United Therapeutics shares rose 12% after TETON-1 met its primary endpoint for Tyvaso in IPF, demonstrating a 130.1 mL improvement in absolute FVC versus placebo.
  • Integrated analyses of TETON-1 and TETON-2 showed a combined treatment effect of 111.8 mL in absolute FVC from baseline to week 52, with benefits observed across subgroups including patients on nintedanib or pirfenidone.
  • The company plans to seek priority review of a supplemental NDA to add IPF to nebulized Tyvaso's labeled indications, with additional data to be presented at the American Thoracic Society meeting in May 2026.

Summary

United Therapeutics Corporation saw its stock rise 12% on Monday after announcing that the TETON-1 pivotal study of its nebulized formulation of treprostinil, Tyvaso, met the trial's primary endpoint for the treatment of idiopathic pulmonary fibrosis (IPF).

Trial outcomes and measured benefits

In TETON-1, nebulized Tyvaso demonstrated superiority over placebo for the primary outcome - change in absolute forced vital capacity (FVC) - with an observed improvement of 130.1 mL. The company also reported a reduction in the risk of clinical worsening among patients receiving the therapy. United Therapeutics noted that the magnitude of treatment effect in TETON-1 exceeded results seen in the earlier TETON-2 study.

Secondary endpoint data showed numerical improvements for Tyvaso relative to placebo in several measures, including time to first acute exacerbation of IPF, changes in percent predicted FVC, K-BILD score, and diffusing capacity for carbon monoxide (DLCO). The company said the therapy reached statistical significance for reducing the risk of clinical worsening and delivered favorable numerical trends across those secondary outcomes.

Integrated analyses and subgroup findings

United Therapeutics combined data from TETON-1 and TETON-2 in integrated analyses, which reported a statistically significant treatment effect compared with placebo from baseline to week 52 for the primary endpoint - change in absolute FVC - by 111.8 mL. The integrated results indicated benefits across all patient subgroups evaluated, explicitly including patients who were receiving background IPF therapies such as nintedanib or pirfenidone.

Safety and regulatory plans

According to the company, treatment with nebulized Tyvaso was well tolerated and the safety profile observed in TETON-1 was consistent with prior Tyvaso studies. United Therapeutics reported that no new safety signals were identified in the dataset.

Following these results, United Therapeutics said it plans to seek priority review of a supplemental New Drug Application and expects to submit the filing to the U.S. Food and Drug Administration by the end of this summer to add IPF to the labeled indications for nebulized Tyvaso. The company also noted that both the FDA and the European Medicines Agency have granted orphan designation for treprostinil for the treatment of IPF.

Next data disclosure

Additional TETON-1 study results and findings from the integrated analyses are scheduled to be presented at the American Thoracic Society Annual Meeting in Orlando in May 2026.

Risks

  • Regulatory review is required before IPF can be added to Tyvaso's labeled indications; the company plans to submit a supplemental NDA for priority review but approval is not guaranteed - this affects biotechnology and pharmaceutical markets.
  • Additional study details will be presented in the future at a medical meeting; until full data are publicly examined, interpretation of efficacy and safety across broader patient populations remains subject to further scrutiny - relevant to healthcare and clinical research sectors.
  • While no new safety signals were observed and Tyvaso was reported as well tolerated in TETON-1, ongoing evaluation of safety and longer-term outcomes will be necessary as the therapy is considered for broader clinical use - an uncertainty for prescribers and payers in the healthcare market.

More from Stock Markets

White House Conducting Review of SEC Plan to Shift Corporate Reporting Cadence Mar 30, 2026 Sysco to Buy Jetro Restaurant Depot in $29 Billion Transaction Mar 30, 2026 Velo3D Stock Climbs After $9.8 Million Defense Agreement Mar 30, 2026 Microsoft expands Copilot with multi-model 'Critique' feature, opens Copilot Cowork to Frontier members Mar 30, 2026 Goldman Opens Coverage of Qualcomm at Neutral, Cites Smartphone Headwinds Countering Industrial Gains Mar 30, 2026